This is a preview of subscription content, log in via an institution to check access.
Reference
E GA, et al. An EARLY Cost-Effectiveness Analysis of Xevinapant in Combination with Chemo-Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck in United States. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN72, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3339/110401
Rights and permissions
About this article
Cite this article
Xevinapant + chemoradiotherapy cost effective for head and neck cancer in the USA. PharmacoEcon Outcomes News 880, 35 (2021). https://doi.org/10.1007/s40274-021-7793-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7793-x